Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40pm ET.
According to the company, the event is virtual and a webcast will be available live and for 90 days via the investor relations section of Corvus' website.
Details
News Market Reaction – CRVS
On Feb 24, the first trading day after this news, CRVS closed 3.54% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Conference edition
- 36th Annual
- Oppenheimer Healthcare Life Sciences Conference
- Presentation time
- 2:40pm ET
- Scheduled on Thursday, February 26, 2026
- Webcast availability
- 90 days
- Replay period following the live presentation
Historical Context
-
Closing of upsized common stock offering with full underwriter option exercise.
-
Pricing of upsized common stock offering at a fixed per-share price.
-
Announcement of proposed common stock and pre-funded warrant offering.
-
Positive Phase 1 soquelitinib results in atopic dermatitis cohort 4.
-
Scheduling announcement for upcoming Phase 1 cohort 4 data release.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at Oppenheimer 36th Annual Healthcare Life Sciences Conference which is being held virtually. The presentation will be on Thursday, February 26, 2026 at 2:40pm ET.
A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.